Iterum Therapeutics plc (ITRMF) Notes Payables (2020 - 2023)

Iterum Therapeutics has reported Notes Payables for 4 years, with the latest figure at $75000.0 in Q3 2023.

• On a quarterly basis, Notes Payables fell 87.7% year-over-year to $75000.0 in Q3 2023; TTM through Sep 2023 was $75000.0, a 87.7% decrease from a year earlier, with the FY2022 full-year figure at $196000.0, down 96.76% from the prior year.
• Notes Payables was $75000.0 for Q3 2023 at Iterum Therapeutics, down from $154000.0 in the prior quarter.
• The five-year high for Notes Payables was $28.9 million in Q1 2021, with the low at $75000.0 in Q3 2023.
• Average Notes Payables over 4 years is $11.9 million, with a median of $6.1 million recorded in 2021.
• The sharpest annual moves came in 2021 and 2022: Notes Payables grew 13.84% in 2021, then tumbled 96.76% in 2022.
• Over 4 years, Notes Payables stood at $28.9 million in 2020, then slumped by 79.01% to $6.1 million in 2021, then sank by 96.76% to $196000.0 in 2022, then tumbled by 61.73% to $75000.0 in 2023.
• The last three Notes Payables figures came in at $75000.0 (Q3 2023), $154000.0 (Q2 2023), and $187000.0 (Q1 2023), per Business Quant data.